Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab

Table 4

Descriptive statistics of anxiety, depression, fatigue, subjective and objective cognitive impairment, and number of patients impaired.

	T0	T1
Anxiety and depression
HADS anxiety (mean, SD)	5.8 (6.0)	6.4 (6.4)
HADS depression (mean, SD)	5.5 (3.4)	5.4 (4.7)
Number of patients (%) with elevated A scores (≥8)	6 (35%)	6 (40%)
Number of patients (%) with elevated D scores (≥8)	7 (41%)	4 (27%)
Number of patients (%) with elevated A and D scores (≥8)	5 (30%)	4 (27%)
Fatigue
FSS (mean, SD)	3.0 (1.8)	3.1 (1.5)
Number of patients (%) with elevated scores (≥4)	7 (41%)	7 (47%)
Subjective cognition
CFQ (mean, SD)	39.8 (23.1)	40.7 (23.7)
Number of patients (%) with elevated scores (≥44)	7 (41%)	7 (47%)
Cognitive computerized test results for processing speed, memory, and executive function composites	T0; ^^^; Mean (SD)	T1; ^^^; Mean (SD)
Processing speed composite	-0.67 (1.00)	-1.20 (0.98)
Memory composite	-0.23 (0.97)	0.03 (0.83)
Executive function composite	-0.31 (0.79)	-0.30 (0.90)
Number (%) of patients impaired on objective computerized testing^^	7 (44%)	4 (33%)

^{^}Cognitive impairment was defined when abnormal performance (z ≤ -1.00) occurred on at least 3 tests of the 7 in the battery. ^{^^}For, respectively, 1 at T0 and 4 patients at 1-year follow-up, no assessment was available.